Seaport Therapeutics
SPTX20.6150.76% ( +0.155 )
Q1 FY2026 EarningsQ2 FY26 results significantly missed consensus on profitability due to massive one-time IPO-related stock-based compensation. GAAP net loss of $62.6M was over 100% wider than the $28.6M expected, while Diluted EPS of -$1.78 missed the -$0.62 mean estimate. The company maintains a strong liquidity position with $427.3M in cash following a successful upsized IPO, providing a runway into 2029 for lead candidates GlyphAllo and GlyphAgo.
Financial report interval: 2025.12.31 - 2026.03.31
Preview: Seaport Therapeutics(SPTX) predict that the EBIT is -27.54 M (--%), Beat estimate;the EPS is -10.34 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITExceed expectations
-0.03B--
-0.03B--
+0.00B--%
EPSMiss expectations
-10.34--
-8.17--
-2.1700--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf